When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S’ ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B ...

Bagsværd, Denmark, 8 November 2024 - The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00 ...

Barclays analyst Emily Field maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...

University of Doha for Science and Technology proudly hosted the 3rd Diabetes Care Symposium under the theme "Empowering ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.